IMPORTANT:

Investors should note that all investments involve risks (including the possibility of loss of the capital invested), prices of fund shares may go up as well as down and past performance is not indicative of future performance. Investors should read the Company's Prospectus (including the Product Key Facts Statement of the Sub-Fund and the full text of the risk factors stated therein) in detail before making any investment decision.

The Stock Exchange of Hong Kong Limited (the "SEHK"), Hong Kong Securities Clearing Company Limited ("HKSCC") and the Securities and Futures Commission (the "SFC") take no responsibility for the contents of this document, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this document.

SFC authorisation is not a recommendation or endorsement of the Sub-Fund nor does it guarantee the commercial merits of the Sub-Fund or their performance. It does not mean the Sub-Fund are suitable for all investors nor is it an endorsement of its suitability for any particular investor or class of investors.

This document is important and requires your immediate attention. If you are in doubt about the contents of this document, you should seek independent professional financial advice.

CSOP ETF Series OFC

(the "**Company**")

((a Hong Kong public umbrella open-ended fund company with variable capital, limited liability and segregated liability between sub-funds and authorized under section 104 of the Securities and Futures Ordinance (Cap. 571) of Hong Kong)

CSOP Hang Seng Biotech ETF

Stock Code: 3174

CSOP NASDAQ 100 ETF

Stock Code of the Listed Class of Shares: 3034

(each a "**Sub-Fund**", collectively the "**Sub-Funds**")

ANNOUNCEMENT

Change of Dealing Deadline

CSOP Asset Management Limited 南方東英資產管理有限公司 (the "**Manager**") notifies shareholders of the CSOP Hang Seng Biotech ETF and the CSOP NASDAQ 100 ETF (the "**Sub-Funds**") in relation to the change of Dealing Deadline of the Sub-Funds with effect from 5 January 2026 (the "**Effective Date**").

Investors should exercise caution in dealing with the shares of the Sub-Funds.

Change of Dealing Deadline

In respect of the CSOP Hang Seng Biotech ETF, the Dealing Deadline for In-Kind Application of Shares of the CSOP Hang Seng Biotech ETF in the primary market will be changed to 4:30 p.m. (Hong Kong time) on the relevant Dealing Day with effect from the Effective Date. For the avoidance of doubt, the Dealing Deadline for In-Cash Application of Shares of the CSOP Hang Seng Biotech ETF does not change.

In respect of the CSOP NASDAQ 100 ETF, the Dealing Deadline for a Creation Application or Redemption Application of the Listed Class of Shares in the primary market and the Dealing Deadline for a subscription application or redemption application of the Unlisted Class of Shares will be changed to 4:00 p.m. (Hong Kong time) on the relevant Dealing Day with effect from the Effective Date.

The receiving time of cleared funds in respect of Creation/Subscription Applications will be set out in the Operational Guideline which will be shared with the relevant Participating Dealer of the Sub-Funds as may be agreed by the Custodian, the Manager and the relevant Participating Dealer.

The Manager believes that this change of the Dealing Deadline will promote trading of shares of the Sub-Funds in the primary market. This change of Dealing Deadline will not affect trading of shares in the Sub-Funds on the SEHK and secondary market investors.

Revised Prospectus

The above changes and consequential amendments will be reflected in the revised Prospectus and Product Key Facts Statements of the Sub-Funds which will be published on the Manager's website at www.csopasset.com and the HKEX's website at www.hkexnews.hk on or before the Effective Date.

General

Unless otherwise defined, all capitalised terms shall have the same meaning as that in the Prospectus of the Sub-Funds.

For Further Information

If you have any queries or require further information in relation to any aspect of this Announcement, please contact our Customer Service Hotline at (852) 3406 5688.

By Order of the Board
CSOP Asset Management Limited
Chief Executive Officer
Ding Chen

2 January 2026

As of the date of this Announcement, the board of directors of the Manager comprises 7 Directors namely, Mr. Zhou Yi, Ms. Chen Li, Mr. Yang Xiaosong, Mr. Cai Zhongping, Ms. Ding Chen, Mr. Wang Qin and Mr. Zhang Huachen.